KLP Kapitalforvaltning AS Buys New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX)

KLP Kapitalforvaltning AS purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 8,400 shares of the company’s stock, valued at approximately $450,000.

Other hedge funds have also recently made changes to their positions in the company. Point72 Asset Management L.P. boosted its position in shares of Janux Therapeutics by 190.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after purchasing an additional 259,445 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Janux Therapeutics by 715.0% in the fourth quarter. Victory Capital Management Inc. now owns 242,409 shares of the company’s stock valued at $12,979,000 after buying an additional 212,664 shares during the period. Skandinaviska Enskilda Banken AB publ grew its position in shares of Janux Therapeutics by 492.2% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 205,167 shares of the company’s stock worth $10,771,000 after buying an additional 170,520 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after acquiring an additional 156,675 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after acquiring an additional 144,883 shares during the period. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Price Performance

NASDAQ JANX opened at $25.77 on Friday. The company has a fifty day moving average price of $34.09 and a 200-day moving average price of $45.29. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -22.03 and a beta of 3.23. Janux Therapeutics, Inc. has a 1 year low of $24.30 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on JANX shares. Wedbush restated an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Scotiabank decreased their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics has an average rating of “Buy” and a consensus target price of $92.44.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. The trade was a 3.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO David Alan Campbell sold 5,000 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the transaction, the chief executive officer now owns 293,054 shares of the company’s stock, valued at approximately $17,583,240. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,668 shares of company stock valued at $548,183 over the last three months. Corporate insiders own 29.40% of the company’s stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.